

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

## Non-consolidated Financial Results for the Three Months Ended June 30, 2025 (Under Japanese GAAP)

July 30, 2025

Company name: Japan Tissue Engineering Co., Ltd.  
 Stock exchange listings: Tokyo Stock Exchange  
 Securities code: 7774  
 URL: <https://www.jppe.co.jp>  
 Representative: Kazuto Yamada, President and CEO  
 Contact: Akinobu Wakabayashi, Director, Corporate Officer, Head of Strategic Planning Office  
 TEL: +81 533-66-2020  
 Supplementary materials for financial summaries: Yes  
 Financial results briefing: None

(Amounts of less than one million yen are rounded down.)

### 1. Non-consolidated Financial Results for the three months ended June 30, 2025 (from April 01, 2025 to June 30, 2025)

#### (1) Operating results

(% represents the change rate from the previous period)

	Net sales		Operating profit		Ordinary profit		Net income	
	Million Yen	%	Million Yen	%	Million Yen	%	Million Yen	%
Three months ended June 30, 2025	426	-3.6	-244	—	-241	—	-242	—
June 30, 2024	442	-33.2	-193	—	-192	—	-211	—
	Basic earnings per share		Diluted earnings per share					
	Yen		Yen					
Three months ended June 30, 2025	-5.97		—					
June 30, 2024	-5.20		—					

(Reference) Investment profit (loss) on equity method Fiscal year ending March 2025 - million yen Fiscal year ended March 2024 - million yen

#### (2) Financial positions

	Total assets	Net assets	Equity to total assets ratio
	Million Yen	Million Yen	%
As of June 30, 2025	6,293	5,582	88.7
March 31, 2025	6,512	5,825	89.4

(Reference) Equity As of June 30, 2025: 5,582 million yen As of March 31, 2025: 5,825 million yen

### 2. Cash dividends

	Annual dividends per share				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	—	0.00	—	0.00	0.00
Fiscal year ending March 31, 2026	—				
Fiscal year ending March 31, 2026 (Forecast)		0.00	—	0.00	0.00

### 3. Non-consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2026 (from April 01, 2025 to March 31, 2026)

	Net sales		Operating profit		Ordinary profit		Net income		Basic earnings per share
	Million Yen	%	Million Yen	%	Million Yen	%	Million Yen	%	Yen
Fiscal year ending March 31, 2026	2,900~3,100	18.1~26.2	100~200	—	110~210	—	100~190	—	2.46~4.68

(Note) Regarding the forecasts for the fiscal year ending March 2026, due to the significant impact of external environmental factors on the nature of our business, and the potential fluctuations in performance during this period, we have omitted the forecasts for the six months ending in the second quarter and disclosed them in a range format.

\* Notes

(1) Adoption of accounting treatment specific to the preparation of quarterly non-consolidated financial statements : None

(2) Changes in accounting policies, Changes in accounting estimates, Retrospective restatement

(i) Changes in accounting policies based on revisions of accounting standard: None

(ii) Changes in accounting policies other than (i): None

(iii) Changes in accounting estimates : None

(iv) Retrospective restatement : None

(3) Number of issued and outstanding shares (common stock)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2025	40,610,200 shares
As of March 31, 2025	40,610,200 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2025	250 shares
As of March 31, 2025	250 shares

(iii) Average number of shares outstanding during the period

Three months ended June 30, 2025	40,609,950 shares
Three months ended June 30, 2024	40,609,954 shares

\* Financial results are not subject to audit by certified public accountants or audit firms.

※ Notes for using forecasted information and Others

(Notice Regarding Forward-Looking Statements)

The forward-looking statements, including performance forecasts, contained in this document are based on information currently available to the company and certain assumptions deemed reasonable. They are not intended as a promise of achievement by the company. Actual performance may differ significantly due to various factors.

**Japan Tissue Engineering Co., Ltd.**  
**Non-consolidated Financial Statements for 1st Quarter of FY2025**  
(April 1, 2025 – June 30, 2025)

**(1) Non-consolidated Balance Sheets**

(Thousands of yen)

	FY2024 As of March 31, 2025	FY2025 1Q As of June 30, 2025
<b>Assets</b>		
Current assets		
Cash and deposits	3,885,449	3,921,460
Notes and accounts receivable - trade	543,573	326,601
Electronically recorded monetary claims - operating	50,625	32,983
Merchandise and finished goods	1,928	-
Work in process	17,142	23,463
Raw materials and supplies	162,629	202,520
Other	163,600	140,260
Total current assets	4,824,949	4,647,290
Non-current assets		
Property, plant and equipment		
Buildings, net	608,302	590,964
Land	582,770	582,770
Other, net	229,182	213,142
Total property, plant and equipment	1,420,255	1,386,876
Intangible assets	96,750	90,867
Investments and other assets	171,034	168,315
Total non-current assets	1,688,040	1,646,060
Total assets	6,512,990	6,293,351
<b>Liabilities</b>		
Current liabilities		
Accounts payable - trade	24,890	36,611
Electronically recorded obligations - operating	84,391	64,061
Income taxes payable	21,264	10,793
Provision for bonuses	127,186	63,342
Provision for bonuses for directors (and other officers)	3,397	-
Other	376,099	503,696
Total current liabilities	637,229	678,504
Non-current liabilities		
Provision for retirement benefits	4,725	2,200
Provision for retirement benefits for directors (and other officers)	46,000	30,000
Total non-current liabilities	50,725	32,200
Total liabilities	687,954	710,704
<b>Net assets</b>		
Shareholders' equity		
Share capital	4,958,763	4,958,763
Capital surplus	2,788,763	2,788,763
Retained earnings	-1,922,179	-2,164,569
Treasury shares	-311	-311
Total shareholders' equity	5,825,035	5,582,646
Total net assets	5,825,035	5,582,646
<b>Total liabilities and net assets</b>	6,512,990	6,293,351

**(2) Non-consolidated Statements of Income**

(Thousands of yen)

	<b>FY2024 1Q</b> Three months ended June 30, 2024	<b>FY 2025 1Q</b> Three months ended June 30, 2025
Net sales	442,310	426,371
Cost of sales	195,218	209,949
Gross profit	247,092	216,421
Selling, general and administrative expenses	440,347	460,813
Operating loss	-193,255	-244,391
Non-operating income		
Interest and dividend income	225	2,466
Income from employee	237	237
Other	128	600
Total non-operating income	592	3,304
Non-operating expenses		
Foreign exchange losses	128	4
Consumption Tax Adjustment	77	119
Other	0	0
Total non-operating expenses	206	123
Ordinary loss	-192,869	-241,210
Loss before income taxes	-192,869	-241,210
Income taxes - current	18,268	1,178
Total income taxes	18,268	1,178
Loss	-211,137	-242,389

**(3) Segment Information**

I. FY2024 (April 1, 2024 – June 30, 2024)

(Unit: Thousands of yen)

	Reportable segments				Reconciling items	Per quarterly financial statements
	Regenerative Medicine Business	Custom Development and Manufacturing Business	LabCyte Business	Reportable segments		
Sales						
Revenues from external customers	301,713	86,353	54,244	442,310	—	442,310
Transactions with other segments	—	—	—	—	—	—
Net sales	301,713	86,353	54,244	442,310	—	442,310
Operating profit (loss)	-12,783	41,188	14,463	42,868	-236,124	-193,255

II. FY2025 (April 1, 2025 – June 30, 2025)

(Unit: Thousands of yen)

	Reportable segments				Reconciling items	Per quarterly financial statements
	Regenerative Medicine Business	Custom Development and Manufacturing Business	LabCyte Business	Reportable segments		
Sales						
Revenues from external customers	262,443	100,434	63,493	426,371	—	426,371
Transactions with other segments	—	—	—	—	—	—
Net sales	262,443	100,434	63,493	426,371	—	426,371
Operating profit (loss)	-35,795	50,673	18,304	33,182	-277,573	-244,391